NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
60 J u l y 20 03 PharmaVOICE Pharma POOL Lynn BAER Dr. Manny BORREGO Novo Nordisk Announces Two Key Appointments for U.S. Medical Department Novo Nordisk, a focused healthcare compa ny and leader in diabetes care, with U.S. headquar ters in Princeton, N.J., has promoted Lynn Baer to senior director and head of clinicaltrial operations, and Manny Borrego, Pharm.D., has been pro moted to director and head of clinical site man agement, reporting to Ms. Baer. Since joining Novo Nordisk last fall as direc tor of clinical project man agement, Ms. Baer has built her new department to maximize best practices for conducting the company’s clinical trials. She directs the newly created clinical trial operations department, which combines the clinical project, site management, and budget groups. Before joining Novo Nordisk, Ms. Baer spent nine years at Quintiles, where she held a variety of clinical operations posi tions of increasing responsibility. Ms. Baer has a bachelor’s degree in zoology from Drew University in Madison and has completed graduate courses in microbiology from Rutgers in Newark. Dr. Borrego joined Novo Nordisk in 1994 as a clinical research associate and was pro moted to regional manager. He has been assis tant director of clinicalsite management for four years and acting director since January. As the U.S. representative of a global company committee, he has been instrumental in the development of Novo Nordisk’s clinical poli cies, procedures, and training programs. In his new capacity, Dr. Borrego continues to recruit, train, and manage fieldbased clinical research associates and relevant inhouse personnel sup porting all of Novo Nordisk’s clinical trials in the United States. Dr. Borrego received a doctor of pharmacy from the Southern School of Pharmacy at Mer cer University and a bachelor’s degree in psy chology from Emory University. Dr. Andrew LOH Baxter Healthcare Appoints Project Management VP Andrew Loh, Ph.D., has joined Baxter Healthcare as VP of project management and pharmaceutical development. He has more than 27 years of experience in the pharmaceutical and biotech industry. He previously was president of AL Associates, a healthcare consulting company where he helped biotech companies develop business plans, preclinical/clinical development plans, and project/portfolio management strategies. Dr. Loh has a MBA in marketing and finance from Indiana University, a doctorate and masters in analytical chemistry from Uni versity of IllinoisUrbana, and a bachelor’s degree in chemistry from Indiana University. Dr. Steven PAUL Lilly Fills Executive VP, Science and Technology,Position With Promotion Eli Lilly has promoted Steven Paul, M.D., to executive VP for science and technology and president of Lilly Research Laboratories. Dr. Paul previously was group VP for Lilly Research Laboratories. The promotion follows the retirement of August Watanabe, M.D., from Indianapolis based Lilly. Dr. Paul joined Lilly in 1993 as VP of cen tral nervous system discovery and decision phase medical research in LRL and was named VP of therapeutic area discovery research and clinical investigation in 1996. Hewas named group VP for Lilly Research Laboratories in 1998. Before joining Lilly, Dr. Paul served as scientific director of the National Institute of Mental Health, as well as chief of the clinical neuroscience branch at NIMH. Dr. Paul received a bachelor of arts degree, magna cum laude with honors, in biology and psychology from Tulane University. He received a master of science degree in anatomy and neuroanatomy and his doctor of medicine degree from the Tulane University School of Medicine. Dr. Paul has authored or coauthored more than 450 papers and book chapters and serves on the editorial boards of numerous scientific journals and as a grant reviewer for several National Institutes of Health committees. He is currently a member of the NIH advisory committee to the director. In addition, he has been listed as one of the most highly cited neuroscientists in the world (19802000) by the Institute of Scien tific Information (ISI). And in 1997, Dr. Paul was elected to membership in the Insti tute of Medicine of the National Academy of Sciences. Kristine PETERSON Biovail Appoints Senior VP, Commercial Operations Biovail has named Kristine Peterson senior VP of commercial operations, with responsi bility for the strategic leadership of Biovail’s U.S. and Canadian commercial operations as well as identifying internal and external growth opportunities. Biovail, based in Mississauga, Ontario, is an international fullservice pharmaceutical company. Ms. Peterson joins Biovail Pharmaceuticals from BristolMyers Squibb where she spent 20 years in increasingly senior roles culminating in her most recent role as senior VP of global marketing, drug discovery, and exploratory development. Ms. Peterson holds a master of business administration as well as a B.S. in marketing, both from the University of Illinois. In addition, William Poole, president of Biovail Pharmaceuticals, has left the company to pursue other career opportunities. TALENT POOL EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY 61 PharmaVOICE J u l y 20 03 TALENT pool Biotech POOL Reggie BOWERMAN Nancy EVERTZ Leon O.MOULDER Jr. MGI Pharma Announces CEO Succession MGI Pharma has named Leon O. Moulder Jr. CEO succeeding Charles N. Blitzer who remains as chairman. MGI Pharma, located in Bloomington, Minn., is an oncologyfocused biopharmaceutical company. Mr. Moulder, 45, has served as president and chief operating officer of MGI since May 2002. He joined MGI as executive VP in September 1999 and has more than 20 years of biopharmaceutical industry experience. Mr. Blitzer, 61, joined MGI as CEO in May 1996 and was appointed chairman in May 2002. MGI also has promoted Reggie Bowerman to VP of marketing. Mr. Bowerman joined MGI in March 2000 and served most recently as senior director of marketing. Nancy Evertz has been promoted to the position of VP of finance and administration. Previously, she was senior director of finance and administration and has been with MGI since July 2000. Craig EBERHARD Dwayne M.ELWOOD Amylin Adds to ManagementTeam Amylin Pharmaceuticals has appointed Dwayne M. Elwood as senior VP of marketing and Craig Eberhard as VP of sales. San Diego based Amylin is a biopharmaceutical company dedicated to developing medicines to improve the lives of people with metabolic diseases. Mr. Elwood and Mr. Eberhard are focused on preparing for the potential commercializa tion of Amylin’s two latestage diabetes prod uct candidates, Symlin (pramlintide acetate) and exenatide (synthetic exendin4). Mr. Elwood has more than 25 years of expe rience in the pharmaceutical industry. Most recently, he was with Corixa/Coulter Pharma ceuticals as senior VP, chief commercial officer, and VP of marketing and sales. Mr. Elwood received his B.S. in business administration with a special emphasis in marketing and accounting from California State University. Before joining Amylin, Mr. Eberhard was regional VP of sales at Pharmacia. During his 21year career with the company and its relat ed premerger companies, he held positions in sales, sales management, corporate training, sales operations, and managed care before assuming the VP of sales position for the Upjohn salesforces. Mr. Eberhard is a graduate of California Lutheran University where he obtained a B.S. in biology. Dr. Michael W. HEARTLEIN TKT Announces Management Changes in Research Department Transkaryotic Thera pies, Cambridge, Mass., a biopharmaceutical com pany developing thera peutics for the treatment of rare genetic diseases caused by protein defi ciencies, has announced that Douglas A. Treco, Ph.D., has resigned as senior VP of research. Michael W. Heartlein, Ph.D., has been pro moted to that position and has overall respon sibility for TKT’s research strategy, including the expansion of the company’s product pipeline beyond its current focus of lysosomal storage disorders. Dr. Heartlein has held a variety of research positions at the company since 1989 and most recently served as VP of molecular biology. Before joining TKT, Dr. Heartlein held a hos pital appointment in genetics at Children’s Hospital Medical Center in Boston and a fac ulty appointment in pediatrics at Harvard Medical School. He received a B.S. in biology from Illinois State University and a Ph.D. in genetics from the University of Tennessee. Gabriel LEUNG OSI Pharmaceuticals Appoints Executive VP and President, Oncology Business OSI Pharmaceuticals has appointed Gabriel Leung as executive VP and president of the oncology business. OSI Pharmaceuti cals, Melville, N.Y., is focused on the discov ery, development, and commercialization of nextgeneration oncology products. Mr. Leung most recently was with Phar macia where he was a group VP of the global prescription business and head of the global oncology franchise. Before Pharmacia, Mr. Leung was a marketing executive in Bristol Myers Squibb’s oncology business. In his role, Mr. Leung’s initial responsibil ities include developing and implementing OSI’s commercial strategy, including devel oping a highquality unit to support market ing, sales, and business development. He is leading a relaunch of Novantrone for cancer indications. In addition, he is responsible for new product development, both from licens ing and acquisitions as well as from OSI’s oncology pipeline. Mr. Leung is a collaborating partner of the National Dialogue on Cancer. Under this ini tiative, Mr. Leung cochairs a special task force to design a new R&D paradigm to help expe dite oncology drug discovery and develop ment. Dr. David R. PARKINSON Amgen Names Head of Oncology Clinical Development David R. Parkinson, M.D., has been appointed as VP and head of the clinical oncol ogy therapeutic area at Amgen, Thousand Oaks, Calif., which discovers, develops, manu factures, and markets human therapeutics based on advances in cellular and molecular biology. Dr. Parkinson’s responsibilities include directing global development efforts in oncol ogy for all of Amgen’s new product candi dates and new indications for marketed prod ucts. Dr. Parkinson brings to the company a wealth of experience in drug development and an international reputation in clinical oncology. Dr. Parkinson joins Amgen from Novartis where he most recently was global head of translational development and a member of the oncology business unit executive committee. Dr. Parkinson received his M.D. from the University of Toronto. Specialty POOL Gian ALIPRANDI Tod MERTES Dr. Andres NEGROVILAR Ligand Announces Managerial Changes Ligand Pharmaceuticals, a San Diegobased specialty pharmaceutical company, has announced several organizational changes designed to improve operational effectiveness and efficiency in R&D, finance, and operations. Andres NegroVilar, M.D., Ph.D., has been promoted to executive VP of research and development and chief science officer. 62 J u l y 20 03 PharmaVOICE TALENT pool Tod Mertes has been promoted to VP and controller. Before joining the company, Mr. Mertes had more than 12 years of experience in public accounting at Pricewaterhouse Coopers. Gian Aliprandi has been promoted to senior VP for technical, supply, and interna tional operations. Mr. Aliprandi has more than 30 years of experience in positions of increas ing responsibility in operations, supply, mate rials management, finance, and control. Tom Silberg, formerly executive VP and chief operating officer, has left Ligand to pur sue other opportunities. Dr. Ernest MARIO Reliant Pharmaceuticals Appoints Chairman and CEO Reliant Pharmaceuti cals has named Ernest Mario, Ph.D., chairman and CEO. Dr. Mario brings more than 35 years of industry experience to the emerging pharmaceu tical company. Dr. Mario previously served as chief executive and deputy chairman of Glaxo, during which time he oversaw the launch of five major brands that grew the company’s sales and profits by nearly 15% annually. In 1993, Dr. Mario joined Alza as CEO, where he ultimately consummated one of the largest mergers in pharmaceutical histo ry. More recently, Dr. Mario founded Apothogen, a company involved in earlystage pharmaceutical development, which subse quently merged with IntraBiotics. Discovery POOL Amy SCHABERG Thomas R. STAAB Dr. Benjamin R. YERXA Inspire Pharmaceuticals Appoints CFO and Announces Promotions Inspire Pharmaceuticals has appointed Thomas R. Staab II to the position of chief financial officer. Inspire also announced the promotion of Benjamin R. Yerxa, Ph.D., from VP of discovery to senior VP of discovery, and the promotion of Amy Schaberg, R.N., B.S.N., from senior director of clinical research to VP of clinical research. Inspire, Durham, N.C., discovers and develops new drugs to treat diseases characterized by deficiencies in the body’s innate defense mechanisms of mucosal hydration and mucociliary clearance, as well as other nonmucosal disorders. Mr. Staab is responsible for the finance and infor mation technology func tions and plays a key role in the development of Inspire’s commercial capa bilities. Mr. Staab previ ously was at Triangle, most recently as VP, trea surer, and acting chief financial officer. Mr. Staab is a certified public accountant and received a B.S. in business administration and a M.S. in accounting from the University of North Carolina. Dr. Yerxa joined Inspire in 1995 from Bur roughs Wellcome and has served as VP of discovery since 2000. He oversees the chemistry, pharmacol ogy, preclinical, and intel lectual property functions and all drugdiscovery and early preclinical development activities. Dr. Yerxa received his Ph.D. in organic chemistry from the University of California at Irvine. Ms. Schaberg joined Inspire in 2001 after having consulted for Inspire for two years. She is responsible for directing the scientific and operational aspects of clinical activities and is the project leader for the allergic rhinitis pro gram. She holds a B.S. in nursing from Boston University. Drug Delivery POOL Dr. John M.SIEBERT CyDex Names President and CEO John M. Siebert, Ph.D., has been named president and CEO and appointed to the board of directors of CyDex, Overland Park, Kan. The company offers advanced drugdelivery solu tions to bring new medications to patients by developing its own pipeline of Captisolenabled proprietary drug formulations and by partner ing with the world’s leading pharmaceutical and biotechnology companies. Dr. Siebert recently served as president and CEO of CIMA Labs, where he led that compa ny’s transition from a small development stage firm to a successful and profitable spe cialty pharmaceutical company based on oral drugdelivery technologies. Dr. Siebert holds a bachelor of science in chemistry from Illinois Benedictine College, a master of science in organic chemistry from Wichita State University, and a Ph.D. in organ ic chemistry from the University of Missouri. CRO POOL Dr. Melanie A.BRUNO Kendle Names Global Regulatory Affairs VP Kendle International, a fullservice contract research organization based in Cincinnati, has named Melanie A. Bruno, Ph.D., MBA, VP of glob al regulatory affairs. Dr. Bruno provides executive leadership and direction to position Kendle and its AAC Consulting Group subsidiary as a global market leader in regulatory consulting services. In this capacity, Dr. Bruno leads teams of specialists with expertise in safety, clinical quality assurance, and compliance and valida tion matters to help expedite the regulatory approval process. Dr. Bruno most recently was an Eli Lilly executive and served as a senior regulatory research scientist in the U.S. regulatory affairs department. Dr. Bruno earned a doctorate of philosophy in developmental biology and a MBA in management and marketing from the University of Cincinnati. Rosa CADINHA Casandra ELVER Peter POWERS PRA Expands Global Team PRA International, a global clinical development organization based in McLean, Va., has expanded its global business devel opment team. Peter Powers has joined the company as director of business develop ment. Mr. Powers manages strategic accounts for PRA and also is responsible for organiz ing sales activities on a global basis. He is based in the Boston area. Rosa Cadinha has been named account exec utive. Her primary responsibility in her new role with the European Business Development Group is to manage existing accounts and to build and maintain business relationships for TALENT pool 64 J u l y 2 00 3 PharmaVOICE the discovery process. In this role, Mr. Donahue leads LION’s North American operations. Mr. Donahue joins LION from Spotfire, where he most recently served as VP of global life sciences and chemicals markets. Mr. Donahue, 40, received degrees in chemistry and computer science from Villanova University. Evrard SPENCER John SUPAN Fast Track Systems Expands Roster Fast Track Systems, a provider of knowledge enabled products and ser vices for optimizing clin ical development, has added two executives to its team. Evrard Spencer has joined as VP of oper ations, and John Supan has joined as VP of finance and chief financial officer. Mr. Spencer brings 20 years of IT and operations experience to Fast Track, San Mateo, Calif. His career includes strategic and project management positions at Ernst & Young Management Consulting Group and BristolMyers Squibb. Mr. Spencer holds a bachelor’s degree in applied mathematics from CarnegieMellon University and a MBA in finance and corporate accounting from the William E. Simon Business School of the University of Rochester. Mr. Supan is a CPA and has more than 25 years of experience. He has served as CFO of public and private com panies including Arg onaut Technologies, Azia Core, and Beacon Diag nostics. Alexander VANDEVERE Cadient Group Adds HighTech Industry Veteran as Marketing Strategist Cadient Group, an online pharmaceutical marketing company located in Conshohocken, Pa., has hired Alexander Vandevere as marketing strategist. With more than 12 years of global interactive agency experience, Mr. Vandevere works with Cadient’s clients to develop online strategies that best achieve their marketing objectives while maximizing their ROI. Mr. Vandevere’s first project is to help develop online consumer and professional strategies for AstraZeneca’s Zomig migraine medicine. Mr. Vandevere most recently was cofounder and managing director of eCity Interactive. He holds a B.S. in telecommuni cations from Kutztown University. MedEd POOL Susan ADAMCZYK Beatrice BENOIT Dr. Jeffery BRUBAKER Dr. Michael DICKMAN Claudia Stahl GAGLIARDI Mary SELTZER Nexus Expands Staff with Industry Veterans Nexus Communica tions, North Wales, Pa., has expanded its staff and capabilities. J e ff e r y B ru b a k e r, Ph.D., has joined Nexus as senior medical writer. Dr. Brubaker joins the company with more than 20 years of research experience in viral and cellular immunology and experimental vac cines. Susan Adamczyk, M.S., has been named senior medical writer. She has worked in vari ous aspects of pharmaceutical research since 1995, including clinical research. Beatrice Benoit joins the company as program director. At Nexus, she draws from her profession al background and knowl edge of multiple therapeu tic areas to direct global projects in nephrology and immunology. Michael Dickman, Ph.D., has been named director of scientific programs. He has more than 20 years experience in clinical research, the European regulatory group. She operates from PRA’s Reading, U.K., office. Casandra Elver has joined the company as an account manager and is responsible for managing accounts that reside within the mountain and central time zones. She works from PRA’s office in Lenexa, Kan. Service POOL Beth BIRKE Mark R. VINCENT EURO RSCG Life NRP Expands Senior ManagementTeam Euro RSCG Life NRP has added two high ly experienced healthcare marketing commu nications professionals. These additions increase the depth and breadth of the agency’s strategic marketing and corporate communica tion practices. Euro RSCG Life is part of Euro RSCG Worldwide, a global marketing com munications agency, and the largest unit of Havas, the world’s sixthlargest communica tions group. Beth Birke, as senior VP, and Mark R. Vin cent, VP, have joined the company’s NewYork headquarters. Ms. Birke, formerly senior VP at Chamber lain Communications Group, also is a former employee of PResence Public Relations, which is now part of NRP. She brings more than 10 years experience in healthcare public relations. She assists the agency in extending and building its client portfolio. Mr. Vincent brings 14 years of healthcare indus try experience to NRP, having served in various management capacities in the pharmaceutical and biotechnology industries. Most recently, Mr. Vin cent was at CuraGen. Joseph F. DONAHUE President Named for LION bioscience North America LION bioscience has appointed Joseph F. Donahue as president. LION bioscience is a global solutions provider for the lifesciences industry that delivers IT solutions to improve TALENT pool 65 PharmaVOICE J u l y 2 00 3 and a decade of experi ence in medical commu nications. Mary Seltzer has been appointed senior project manager. Ms. Seltzer has worked in the medical education/communica tions field for more than eight years. Her previous experience includes 10 years in advertising pro duction. At Nexus, she manages projects for neu rology and psychiatry products. Claudia Stahl Gagliar di joins the company as manager of programs and communications. She has worked in medical education for four years and healthcare communications for 12 years. Agency POOL Dr.Richard ALEXANDER Antoinette CAMPO Dr. Jeffrey FISHER Jacquelyn HILL Kenneth HOERNER Jeannine LEE Kathleen MILBURN John J. NOSTA Kim PERSSON Keir ROTHNIE Jennifer STEEBER CommonHealth Agencies Announce Hires Noes i s Hea l thcare Interactions, Common Health ‘s pro f ess i ona l advertising and promo tion unit, has appointed John J. Nosta as executive VP and chief creative officer. In his new position at Noesis, located in Morristown, N.J., Mr. Nosta is overseeing the execution of all aspects of creative development. In addition, he plays a vital role in devel oping growth strategies for the agency and for managing current and future clients. Before joining Noesis, Mr. Nosta held the title of managing partner at MDC Group. Mr. Nosta also has held senior positions at several major agencies, including KPR and Lyons Lavey Nickel Swift, where he served as executive VP and associate creative director. In other agency news, Health Learning Systems, Wayne, N.J., the found ing medicaleducation unit of CommonHealth, has named Jeffrey Fisher, M.D., as an executive VP, medical director, business development. He also serves in the same capacity at Adient, a HLS sister company and a CommonHealth profes sional advertising and promotion unit. Previously, Dr. Fisher was employed with MPE Communications, a division of Torre Lazur McCann Hea l t hca r e WorldWide as executive VP and medical director. Jeannine Lee comes to HLS as a program direc tor. Previously, Ms. Lee was a senior account exec utive at Adient. Richard Alexander, Ph.D., has joined HLS as a medical writer. Previously, Dr. Alexander was with Advanced Viral Research as group leader of the Immunology Research Group. Jennifer Steeber has joined HLS as a medical writer. Before joining HLS, Ms. Steeber was a graduate student at the State University of New York at Albany. Antoinette Campo has been hired as an editor. Before her employment with HLS, Ms. Campo was a freelance copy editor for Medical Action Com munications. Kenneth Hoerner has been hired as a senior graphic designer. Before joining HLS, Mr. Hoerner worked as a freelance graphic designer. In additional Com monHealth news, Keir Rothnie has joined The Conectics Group, Parsippany, N.J., in the position of VP of new business development. Previously, he was a business development executive with Soft Watch Inc. Kathleen Milburn also has joined The Conectics Group, another Com monHealth division. She comes to the agency as a project manager. Before joining the agency, Ms. Milburn held the title of VP of client services at GlobalWorks. Kim Persson has been hired at The Conectics Group as a project man ager. Previously, she had been a training and con tinuous improvement manager at Berlex Labora tories. Jacquelyn Hill has joined The Conectics Group as a media plan ner. Previously, Ms. Hill was an assistant media planner at Cline, Davis & Mann. Alissa COLETTA Jucinda FENNHODSON Julie MCDONOUGH Rick MCGUIRK Kevin MURRAY Julie PRIDDLE Judith SUPLEY Danae Fogarty WALSH Melissa WOJCIK Palio Announces Appointments and Promotions Palio Communications, Saratoga Springs, N.Y., a fullserice communications agency and part of the inChord net work, has announced agency appointments and promotions. Jucinda FennHodson has been appointed VP of multicultural marketing. Ms. FennHodson brings more than 10 years of TALENT pool 66 J u l y 20 03 PharmaVOICE pharmaceutical industry experience to the agency. Most recently, Ms. FennHodson was a consultant at Fenn Allen Consulting Group, where her strategic partnership development counsel helped major corporations reach their goals and objectives in several multicultural markets. Palio also has promoted Alissa Coletta from account coordinator to assistant account execu tive; Julie McDonough, from assistant account executive to account exec utive; and Kevin Murray, from senior account execu tive to account supervisor. Ms. Coletta joined Palio in 2001 and received her bachelor’s degree from Syracuse University. Ms . McDonough ‘s p re v i ou s expe r i ence includes more than 15 years of destination marketing and planning with the Saratoga Convention and Tourism Bureau. Mr. Murray, who joined Palio in 2002, has been an integral part of the account services team, bringing client perspec tive and product manage ment expertise. Danae Fogarty Walsh has been named project/broadcast manag er at Palio. Previously, she was a broadcast producer at Arnold Worldwide, where she was responsible for managing all aspects of radio and television commercial production for a variety of clients. Rick McGuirk, who has been named graphic designer at Palio, brings more than 20 years of design experience to the agency. Julie Priddle has been named account executive. She has an extensive back ground in event planning and project management. She had been a director of marketing and promotions at Candice Carpenter. Judith Supley has been promoted from assistant account execu tive to account executive. Ms. Supley joins Palio from Pfizer, where her most recent position was director of customer knowledge management for market opera tions and customer ecommerce. Melissa Wojcik has moved from account executive to senior account executive. Ms. Wojcik has pharmaceutical, medical device, biotechnology, and lifesciences industry expe rience. Before joining Palio, she was a senior account executive at Lowe Grob Health & Sci ence. Steve DUSENBERRY Jeff TOMASO inChord Appointments Announced inChord Communica tions, one of the largest independent marketing communications organi zations in the world, has added to its staff. GSW, an inChord agency located in Colum bus, Ohio, has named Steve Dusenberry as senior VP/group creative director. In this role, Mr. Dusenberry is responsible for establishing and managing all creative work for GSW’s consumer business development division. Before joining GSW, Mr. Dusenberry was senior VP/group creative director at BBDO Chicago. Blue Diesel, an inter active marketing unit of inChord Communica tions, has named Jeff Tomaso director, strategic development. In this role at Blue Diesel, Mr. Tomaso is responsible for creating marketing strategies to help clients realize their goals through the use of Webbased and interactive applications, as well as leading new business efforts for the company. He is based in Saratoga Springs, N.Y., where he is working closely with one of Blue Diesel’s sis ter companies, Palio Communications, a full service advertising agency. Most recently, Mr. Tomaso held the posi tion of principal partner in the executive man agement team for Epoch Strategy. Elaine HEIMBERGER Integrated Communications Names SeniorVP Elaine Heimberger has been appointed senior VP and associate creative director of copy on the Novartis brands at Integrated Communications, a full service healthcare market ing communications agency located in Parsip pany, N.J., and part of Lowe Healthcare World wide. Her brand repsonsibil ities include Trileptal, an antiepileptic; Lamisil, an antifungal; Exelon, Novartis’ treatment for Alzheimer’s disease; and Miacalcin Nasal Spray for the treatment of osteoporosis. Ms. Heimberger has more than 20 years experience writing on a broad spectrum of therapeutic categories. She rejoins Integrated after a sixyear tenure at two CommonHealth agencies. She worked for CommonHealth’s Adient as a senior VP and associate creative director. Before Adient, she was at Thomas Ferguson. Carl ROSELLE Stedman STEVENS HealthSTAR Annouces Key Hires HealthSTAR Communications has hired Carl Roselle as senior VP of network develop ment. In his new role, Mr. Roselle represents the HealthSTAR network of companies to the pharmaceutical industry. HealthSTAR, Woodbridge, N.J., is one of the largest healthcare marketing services net works in the industry. Before joining HealthSTAR, Mr. Roselle was senior VP of sales with MediPromotions. He brings nearly 20 years of experience in medical marketing and advertising, including positions as publisher and VP, group publish er respectively with Romaine Pierson and Job son Publishing. Additionally, he has held sales and sales training positions with Ortho Pharmaceutical. In related news, Sted man Stevens, president of Pharmaceutical Research Plus, has been given the added responsibility of chief operating officer. P h a rm a c e u t i c a l Research Plus is a leading patientrecruitment com pany and part of the HealthSTAR Communica tions network. Mr. Stevens has more than 17 years of man agement experience at the CEO and board level in pharmaceutical, drug channel distri bution, physician marketing, hospital, and consumer products arenas. Please send your personnel announcements to email@example.com.